Research analysts at Cantor Fitzgerald initiated coverage on shares of Aimmune Therapeutics (NASDAQ:AIMT) in a report issued on Tuesday, The Fly reports. The firm set an “overweight” rating on the biotechnology company’s stock.
AIMT has been the topic of a number of other reports. Piper Jaffray Companies set a $38.00 price target on Aimmune Therapeutics and gave the company a “buy” rating in a research note on Saturday, October 21st. Zacks Investment Research upgraded Aimmune Therapeutics from a “sell” rating to a “hold” rating in a research note on Tuesday, August 29th. Wedbush restated an “outperform” rating and issued a $70.00 price target on shares of Aimmune Therapeutics in a research note on Friday, December 1st. Roth Capital started coverage on Aimmune Therapeutics in a research note on Monday, November 20th. They issued a “buy” rating and a $60.00 price target on the stock. Finally, ValuEngine downgraded Aimmune Therapeutics from a “hold” rating to a “sell” rating in a research note on Friday, December 1st. One equities research analyst has rated the stock with a sell rating, two have given a hold rating and five have assigned a buy rating to the stock. The company presently has a consensus rating of “Buy” and a consensus price target of $53.80.
Aimmune Therapeutics (NASDAQ AIMT) traded down $0.56 during trading on Tuesday, hitting $33.60. The company had a trading volume of 353,296 shares, compared to its average volume of 357,499. Aimmune Therapeutics has a 12-month low of $15.97 and a 12-month high of $38.86.
In other Aimmune Therapeutics news, insider Douglas T. Sheehy sold 3,750 shares of the business’s stock in a transaction on Thursday, November 30th. The stock was sold at an average price of $37.00, for a total transaction of $138,750.00. Following the sale, the insider now directly owns 3,750 shares in the company, valued at $138,750. The transaction was disclosed in a document filed with the SEC, which can be accessed through the SEC website. Also, insider Douglas T. Sheehy sold 1,906 shares of the business’s stock in a transaction on Monday, December 4th. The stock was sold at an average price of $38.66, for a total value of $73,685.96. Following the sale, the insider now owns 1,906 shares in the company, valued at $73,685.96. The disclosure for this sale can be found here. Over the last quarter, insiders have sold 274,986 shares of company stock worth $7,533,100. 17.59% of the stock is owned by company insiders.
A number of institutional investors and hedge funds have recently bought and sold shares of the business. SG Americas Securities LLC boosted its position in Aimmune Therapeutics by 10.1% during the second quarter. SG Americas Securities LLC now owns 5,451 shares of the biotechnology company’s stock worth $112,000 after purchasing an additional 499 shares in the last quarter. Teachers Advisors LLC raised its holdings in shares of Aimmune Therapeutics by 2.6% in the first quarter. Teachers Advisors LLC now owns 44,349 shares of the biotechnology company’s stock worth $964,000 after acquiring an additional 1,120 shares during the last quarter. Legal & General Group Plc raised its holdings in shares of Aimmune Therapeutics by 26.6% in the second quarter. Legal & General Group Plc now owns 7,776 shares of the biotechnology company’s stock worth $160,000 after acquiring an additional 1,634 shares during the last quarter. American International Group Inc. raised its holdings in shares of Aimmune Therapeutics by 8.1% in the third quarter. American International Group Inc. now owns 23,591 shares of the biotechnology company’s stock worth $585,000 after acquiring an additional 1,764 shares during the last quarter. Finally, Strs Ohio raised its holdings in shares of Aimmune Therapeutics by 6.1% in the second quarter. Strs Ohio now owns 34,600 shares of the biotechnology company’s stock worth $711,000 after acquiring an additional 2,000 shares during the last quarter. Institutional investors own 73.34% of the company’s stock.
TRADEMARK VIOLATION NOTICE: This piece was originally published by American Banking and Market News and is the sole property of of American Banking and Market News. If you are accessing this piece on another publication, it was illegally stolen and republished in violation of U.S. & international copyright & trademark legislation. The correct version of this piece can be viewed at https://www.americanbankingnews.com/2017/12/12/aimmune-therapeutics-aimt-receives-new-coverage-from-analysts-at-cantor-fitzgerald.html.
About Aimmune Therapeutics
Aimmune Therapeutics, Inc is a clinical-stage biopharmaceutical company developing a therapeutic approach, including the development of product candidates, for the treatment of peanut and other food allergies. The Company’s therapeutic approach, which it refers to as Characterized Oral Desensitization Immunotherapy (CODIT), is a system designed to desensitize patients to food allergens using characterized biologic products, defined treatment protocols and support services.
